EUVIMEDEUVIMED entdecken
Crossref

Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab

A M G A Laheij iD, N W C J van de Donk iD

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-023-08233-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von A M G A Laheij und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Medicine, Academic Center for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit, Gustav Mahlerlaan 3004, 1008, L…. Hauptthemen laut MEDLINE: Multiple Myeloma, Xerostomia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: In recent years, various immunotherapies have improved the survival of patients with multiple myeloma (MM). However, there remains an unmet need for novel agents. Talquetamab is the first-in-class GPRC5D-targeting T-cell redirecting bispecific antibody, which has substantial activity in advanced MM. Rapidly after the start of talquetamab treatment, patients reported taste changes (dysgeusia; 60% of patients), and a feeling of dry mouth (xerostomia; 30-57% of patients), which may be related to expression of the target antigen in healthy tissues, such as taste buds. Here, we aimed at better characterizing these oral toxicities. METHODS: We measured salivary flow and the ability to taste (objectively and patient-reported), assessed the feeling of dry mouth, and evaluated quality of life before and 8 weeks after the start of talquetamab therapy in eight heavily pretreated MM patients. RESULTS: Talquetamab treatment led to the rapid and significant decrease in objectively measured taste scores (total score 8.8 ± 2.0 vs 4.9 ± 2.5). All patients reported moderate to severe taste changes. Moreover, patients experienced severe xerostomia after the initiation of talquetamab treatment, in the absence of changes in unstimulated and stimulated salivary flow. Because of these oral toxicities a significant impairment in global health status/(oral health related) quality of life was reported. CONCLUSION: Studying taste changes in patients treated with talquetamab following up on the described leads provides a new and unique opportunity to further unravel the pathophysiology of taste changes after cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaXerostomiaHumansDysgeusiaQuality of LifeT-LymphocytesReceptors, G-Protein-Coupled

Stichwörter der Autor:innen

Bispecific antibodyDysgeusiaImmunotherapyMultiple myelomaXerostomia

Substanzen

GPRC5D protein, humanReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • Department of Oral Medicine, Academic Center for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit, Gustav Mahlerlaan 3004, 1008, LA, Amsterdam, the Netherlands. a.laheij@acta.nl.
  • Department of Oral and Maxillofacial Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. a.laheij@acta.nl.
  • Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.

ORCID-Profile: A M G A Laheij, N W C J van de Donk

Zitieren

APA

Laheij, A. M. G. A., & van de Donk, N. W. C. J. (2024). Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab. Supportive Care in Cancer. https://doi.org/10.1007/s00520-023-08233-0

Vancouver

Laheij AMGA, van de Donk NWCJ. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab. Supportive Care in Cancer. 2024. doi:10.1007/s00520-023-08233-0

BibTeX
@article{Laheij2024,
  author = {Laheij, A M G A and van de Donk, N W C J},
  title = {Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-023-08233-0}
}
Kostenlos starten →